Reckitt shares lift after Dettol and Durex help sales growth

Shares in Reckitt climbed in early trading as investors also welcomed reassurance from bosses over US litigation linked to baby formula.

Henry Saker-Clark
Wednesday 24 April 2024 07:36 EDT
The boss of household goods giant Reckitt said there was room to ‘sharpen and improve’ under a strategy overhaul (Alamy/PA)
The boss of household goods giant Reckitt said there was room to ‘sharpen and improve’ under a strategy overhaul (Alamy/PA)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Consumer goods giant Reckitt revealed stronger-than-expected sales for the past quarter, as it cheered growth for brands including Dettol, Durex and Finish.

Shares in Reckitt climbed in early trading as investors also welcomed reassurance from bosses over US litigation related to its premature baby formula business.

It comes after the firm’s stock had dropped by around a third over the past 12 months amid pressure from shoppers opting for cheaper, supermarket own-brand alternatives.

The company, which also makes Nurofen and Strepsils, said on Wednesday that group like-for-like sales grew by 1.5% to £3.73 billion over the first quarter of 2024.

Nevertheless, sales volumes dipped slightly by 0.5% as higher pricing continued to support growth.

Kris Licht, chief executive officer, stressed that it represented a “good” quarter for the business and said it is “returning to a more balanced contribution from price, mix and volume” amid easing inflation.

The firm’s hygiene operation saw sales grow by 7.1% for the quarter, with sales volumes up 2.9%.

Key Reckitt brands such as Lysol, Dettol, Durex and Finish all sold higher volumes over the period.

The company’s nutrition operation remained its weakest performing area, with sales down 9.9% amid a 9.4% drop in volumes bought by shoppers.

This was partly linked to a boost in the previous year after supply issues at a major competitor.

The firm’s nutrition business has also come under pressure over potential large liabilities from lawsuits in the US related to its Enfamil Premature 24 baby formula, following a ruling in Illinois last month.

The company, which has rejected the ruling, has vowed it will continue to sell the products and said the US nutrition business is still performing well.

Mr Licht added: “We are well placed to deliver value creation by leveraging our strong portfolio of brands through investment and innovation.

“This drives our continued strong free cashflow generation, our accelerated share buyback programme and increased cash returns to shareholders.”

Reckitt shares were 4.8% higher at 4,453p on Wednesday morning.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in